Patents Assigned to THERAPEUTICS, INC.
  • Sting agonist compounds and methods of use
    Patent number: 11939343
    Abstract: The present disclosure relates to STING (Stimulator of Interferon Genes) agonist compounds, methods of making the compounds and their methods of use.
    Type: Grant
    Filed: September 9, 2021
    Date of Patent: March 26, 2024
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Jeremy R. Duvall, Keith W. Bentley, Brian D. Jones, Eugene W. Kelleher, Soumya S. Ray, Joshua D. Thomas, Dorin Toader
  • Translatable molecules and synthesis thereof
    Patent number: 11939363
    Abstract: A range of therapeutic mRNA molecules expressible to provide a target polypeptide or protein. The RNA molecules can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided are DNA templates, which can be transcribed to provide a target mRNA, and can have altered nucleotides, such as reduced deoxyadenosines. Also provided are processes for making the therapeutic mRNA molecules. The RNA molecules can be translated in vitro or in vivo to provide an active polypeptide or protein. The RNA molecules can be included in a composition used for preventing, treating, or ameliorating at least one symptom of a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: March 26, 2024
    Assignee: ARCTURUS THERAPEUTICS, INC.
    Inventors: Pattraranee Limphong, Kiyoshi Tachikawa, Padmanabh Chivukula, Daiki Matsuda, Arisa Cale
  • Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
    Patent number: 11938295
    Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: March 26, 2024
    Assignee: Biora Therapeutics, Inc.
    Inventors: Jeffrey A. Shimizu, Mitchell Lawrence Jones, Mark Sasha Drlik, Iman Niknia, Nathan John Muller, Tuyen Nguyen, Christopher Loren Wahl, Edward Mudge, Nicholas Mark Salt, Nia Eleri Stevens, Stuart Robert Abercrombie, Christopher Ian Bunce, Ryan Elliott Jones, Kevin Howe, Pejman Rahimian, Nelson Quintana
  • Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG
    Patent number: 11939335
    Abstract: Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: March 26, 2024
    Assignee: 858 THERAPEUTICS, INC.
    Inventors: James M. Veal, Jeffrey A. Stafford, Donald S. Karanewsky, Shyama Herath
  • Lipid nanoparticles encapsulation of large RNA
    Patent number: 11938227
    Abstract: A method of producing lipid-encapsulated RNA nanoparticles includes flowing an aqueous solution comprising an RNA through a 1st tube having a first inner diameter (ID); the RNA comprises from about 6,000 to about 13,000 nucleotides; flowing an ethanol solution comprising lipids through a 2nd tube having a second inner diameter (ID), at a flow rate of about 0.2 to about 1 times relative to the aqueous solution through the 1st tube, the lipids comprise a cationic lipid; and mixing the ethanol solution with the aqueous solution; the first ID and second ID and flow rates through the 1st tube and 2nd tube are selected to produce a shear force sufficiently low to preserve the integrity of the RNA; the mixing produces an output solution flowing in the 1st tube comprising a turbulent flow of the RNA and the lipids in between about ethanol, the lipid-encapsulated RNA nanoparticles having a bilayer structure.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: March 26, 2024
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Yanjie Bao, Brenda Clemente, Priya Prakash Karmali
  • Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
    Patent number: 11938101
    Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: March 26, 2024
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Paul Mollard, Peter Giannousis, Shazad Suchit, Mahmoud Mirmehrabi, Christopher R. Cornell, Kieron E. Wesson
  • B7-H4 antibodies and methods and use thereof
    Patent number: 11939383
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4. The anti-B7-H4 antibodies or antigen-binding fragments thereof are useful, for example in detecting B7-H4. Immunohistochemistry (IHC) can be used to detect B7-H4. The present disclosure also provides methods for treating cancer wherein increased B7-H4 has been detected, by administering a therapeutic anti-B7-H4 antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: March 26, 2024
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Charles Kaplan, Alessandro Palumbo, Kathy Miller, Hangil Park, Nerissa Mendoza, Majid Ghoddusi
  • Treatments with nirogacestat
    Patent number: 11938116
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: March 26, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Antibody variable domains targeting the NKG2D receptor
    Patent number: 11939384
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: March 26, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Methods and compositions for targeting PD-L1
    Patent number: 11939581
    Abstract: The present disclosure relates to small interfering RNA (siRNA) molecules directed to mRNA transcripts of CD274 to cause downregulation of programmed death-ligand 1 (PD-L1) expression in humans. The siRNA can be constructed of unmodified nucleotides or modified nucleotides that exhibit modified sugars, nucleobases, linkages, or covalently bound targeting moieties. Also disclosed herein are pharmaceutical compositions of siRNAs and uses of or methods of using the siRNAs for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: March 26, 2024
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Megan Elizabeth Fitzgerald, Saul Martinez Montero, Aneerban Bhattacharya
  • Antibodies against microorganisms and uses thereof
    Patent number: 11939371
    Abstract: Described herein are methods and antibodies useful for reducing, eliminating, or preventing infection with a bacterial population in domestic animals or humans. Also described herein are antigens useful for targeting by heavy chain antibodies and VHH fragments for reducing a bacterial population in domestic animals or humans.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: March 26, 2024
    Assignee: NOVOBIND LIVESTOCK THERAPEUTICS INC.
    Inventor: Hamlet Abnousi
  • Pharmaceutical compositions and methods targeting Wnt pathway proteins
    Patent number: 11938167
    Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: March 26, 2024
    Assignees: ENZO BIOCHEM, INC., ENZO THERAPEUTICS, INC.
    Inventors: Joshua Rabbani, Xiaofeng Li, James J. Donegan
  • Methods of making a modulator of hemoglobin
    Patent number: 11939323
    Abstract: The present disclosure relates to processes for preparing a compound of formula I: The disclosure also provides compounds that are synthetic intermediates.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: March 26, 2024
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Xiang Wang, Shinji Fujimori, Todd Daniel Nelson, Ana Cristina Parra Rivera, Devon Mundal, Benjamin Graetz, Morin M. Frick
  • Compositions of peptide inhibitors of Interleukin-23 receptor
    Patent number: 11939361
    Abstract: The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: March 26, 2024
    Assignees: Janssen Pharmaceutica NV, Protagonist Therapeutics, Inc.
    Inventors: Giustino Di Pretoro, Dajun Sun, Gopal Rajan, Geraldine Broeckx, Nathalie Mertens, Shu Li, Felix Lai, Mohammad Masjedizadeh, Anne M. Fourie, Beverly Knight, David Polidori, Santhosh Francis Neelamkavil, Nishit Modi, Ashok Bhandari, Xiaoli Cheng
  • ADAPTIVE SELECTION OF STIMULI FOR NEURO-ACTIVATION
    Publication number: 20240090809
    Abstract: Provided herein are systems and methods of associating stimuli with conditions of users. A computing system may identify, in response to presenting a first stimulus to a user, a relevance value of the first stimulus indicative of a relevance of the first stimulus with a condition of the user. The computing system may classify, responsive to the relevance value satisfying a threshold, the first stimulus as having a non-neutral reaction type associated with the condition to the user. The computing system may store, in one or more data structures, an association between the user and the first stimulus classified as having the non-neutral reaction type for presenting in a therapy session to address the condition of the user. The computing system may provide instructions for presenting the first stimulus in the therapy session to address the condition of the user.
    Type: Application
    Filed: September 14, 2023
    Publication date: March 21, 2024
    Applicant: Click Therapeutics, Inc.
    Inventor: Jacqueline LUTZ
  • FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE
    Publication number: 20240092721
    Abstract: This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof.
    Type: Application
    Filed: June 1, 2023
    Publication date: March 21, 2024
    Applicant: Espervita Therapeutics, Inc.
    Inventor: Daniela Carmen ONICIU
  • Antibodies Binding to VISTA at Acidic pH
    Publication number: 20240092907
    Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
    Type: Application
    Filed: February 1, 2023
    Publication date: March 21, 2024
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
  • VARIANT IGF2 CONSTRUCTS
    Publication number: 20240091321
    Abstract: Provided herein are novel IGF2 peptides, fusion proteins, and nucleic acid sequences encoding novel IGF2 peptides and fusion proteins for the treatment of lysorsomal storage disorders, wherein the IGF2 peptides confer enhanced properties, such as enhanced expression, secretion and cellular uptake. The constructs provided herein are useful in treating lysosomal storage disorders by both enzyme replacement therapy and gene therapy.
    Type: Application
    Filed: October 12, 2020
    Publication date: March 21, 2024
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Hung V. Do, Steven Tuske, Russell Gotschall, Ce Feng Liu
  • Treatment of amyotrophic lateral sclerosis (ALS)
    Patent number: 11931375
    Abstract: The present disclosure relates to AAVs encoding a SOD1 targeting polynucleotide which may be used to treat amyotrophic lateral sclerosis (ALS) and delivery methods for the treatment of spinal cord related disorders including ALS.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: March 19, 2024
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee Sah, Holger Patzke, Qingmin Chen, Jenna Carroll Soper
  • Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases
    Patent number: 11931345
    Abstract: Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: March 19, 2024
    Assignee: Cirius Therapeutics, Inc.
    Inventor: Gerard R. Colca